Page 25 - 2021_12-Haematologica-web

Adenovirus vaccines and thrombosis
Microbiol. 2020;5(10):1185-1191.
51. Hamada F, Aoki M, Akiyama T, Toyoshima K. Association of immunoglobulin G Fc receptor II with Src like protein-tyrosine kinase Fgr in neutrophils. Proc Natl Acad
Sci U S A. 1993;90(13):6305-6309.
52. Ghazizadeh S, Bolen JB, Fleit HB. Physical and functional association of Src-related protein tyrosine kinases with Fc gamma RII in monocytic THP-1 cells. J Biol Chem.
1994;269(12):8878-8884.
53. Kiener PA, Rankin BM, Burkhardt AL, et al.
Cross-linking of Fc gamma receptor I (Fc gamma RI) and receptor II (Fc gamma RII) on monocytic cells activates a signal trans- duction pathway common to both Fc receptors that involves the stimulation of p72 Syk protein tyrosine kinase. J Biol Chem. 1993;268(32):24442-24448.
54. Nimmerjahn F, Ravetch JV. Fcγ receptors as regulators of immune responses. Nat Rev Immunol. 2008;8(1):34-47.
55. Joshi T, Butchar JP, Tridandapani S. Fcg receptor signaling in phagocytes. Int J Hematol. 2006;84(3):210-216.
56. Furuyama W, Marzi A, Carmody AB, et al. Fcg-receptor IIa-mediated Src signaling pathway is essential for the antibody- dependent enhancement of Ebola virus infection. PLoS Pathog. 2016;12(12): e1006139.
57. Taylor SM, Reilly MP, Schreiber AD, Chien P, Tuckosh JR, McKenzie SE. Thrombosis and shock induced by activating antiplatelet antibodies in human Fc gamma RIIA transgenic mice: the interplay among antibody, spleen, and Fc receptor. Blood. 2000;96(13):4254-4260.
58. Calverley DC, Brass E, Hacker MR, et al. Potential role of platelet FcgammaRIIA in col- lagen-mediated platelet activation associated with atherothrombosis. Atherosclerosis. 2002;164(2):261-267.
59.Pamela S, Anna Maria L, Elena D et al. Heparin-induced thrombocytopenia: the role of platelets genetic polymorphisms. Platelets. 2013;24(5):362-368.
60. Tetro JA. Is COVID-19 receiving ADE from other coronaviruses? Microbes Infect. 2020;22(2):72-73.
61. Collocca S, Barnes E, Folgori A, et al. Vaccine vectors derived from a large collec- tion of simian adenoviruses induce potent cellular immunity across multiple species. Sci Transl Med. 2012;4(115):115ra2.
62. Obdulio GN, V'kovski V, Zettl F, Zimmer G, Thiel V, Summerfield A. No evidence for human monocyte-derived macrophage infection and antibody-mediated enhance- ment of SARS-CoV-2 Infection. Front Cell Infect Microbiol. 2021;11:644574.
63. Crystal RG, Harvey BG, Wisnivesky JP, et al. Analysis of risk factors for local delivery of low- and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of comorbid conditions. Hum Gene Ther. 2002;13(1):65-100.
64. Folegatti PM, Bittaye M, Flaxman A, et al. Safety and immunogenicity of a candidate Middle East respiratory syndrome coron- avirus viral-vectored vaccine: a dose-escala- tion, open-label, non-randomised, uncon-
trolled, phase 1 trial. Lancet Infect Dis.
2020;20(7):816-826.
65. Kupferschmidt K, Vogel G. What’s the
future of vaccines linked to rare clotting disorders? Science breaks down the latest. 2021 May 3. [Epub ahead of print]
66. Jaoko W, Karita E, Kayitenkore K, et al. Safety and immunogenicity study of multi- clade HIV-1 Adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in Africa. PLoS One. 2010;5(9):e12873.
67. Keefer MC, Gilmour J, Hayes P, Gill D, et al. A phase I double blind, placebo-con- trolled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vac- cine in healthy uninfected adults. PLoS One. 2012;7(8):e41936.
68.Rego GNA, Nucci MP, Alves AH, et al. Current clinical trials protocols and the global effort for immunization against SARS-CoV-2. Vaccines (Basel). 2020;8(3): 474.
69. Van Doremalen N, Lambe T, Spencer A, et al. ChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2 pneumonia in rhesus macaques. Nature. 2020;586(7830):578-582.
70.Folegatti PM, Ewer KJ, Aley PK, et al. Oxford COVID Vaccine Trial Group. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS- CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020;396(10249):467-478.
71. Sandoff J, Gray G, Vandebosch A, et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. N Engl J Med. 2021;384(23):2187-2201.
72. Logunov DY, Dolzhikova IV, Shcheblyakov DV, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime- boost COVID-19 vaccine: an interim analy- sis of a randomized controlled phase 3 trial in Russia. Lancet. 2021;397(10275):671- 681.
73. Pottegård A, Lund LC, Karlstad Ø, et al. Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vac- cination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study. BMJ. 2021;May 5;373:n1114.
74. Marcucci R, Berteotti M, Gori AM, et al. Heparin induced thrombocytopenia: posi- tion paper from the Italian Society on Thrombosis and Haemostasis (SISET). Blood Transfus. 2021;19(1):14-23.
75.Cuker A, Arepally GM, Chong BH, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. Blood Adv. 2018;2(22): 3360-3392.
76. Greinacher A, Farner B, Kroll H, et al. Clinical features of heparin-induced throm- bocytopenia including risk factors for thrombosis. A retrospective of 408 patients. Thromb Haemost. 2005;94(1): 132-135.
77. Greinacher A, Selleng K, Warkentin TE. Autoimmune heparin-induced thrombocy- topenia. J Thromb Haemost. 2017;15(11):
2099-2114.
78. Warkentin TE, Greinacher A. Spontaneous
HIT syndrome: knee replacement, infec- tion, and parallels with vaccine-induced immune thrombotic thrombocytopenia. Thromb Res. 2021;204:40-51.
79. Huynh A, Kelton JG, Arnold DM, Daka M, Nazy I. Antibody epitopes in vaccine- induced immune thrombotic thrombocy- topenia. Nature. 2021;596(7873):565-569.
80. Favaloro EJ. Laboratory testing for suspect- ed COVID-19 vaccine-induced (immune) thrombotic thrombocytopenia. Int J Lab Hematol. 2021;43(4): 559-570
81. Vayne C, Guery EA, Kizlik-Masson C, et al. Beneficial effect of exogenous platelet fac- tor 4 for detecting pathogenic heparin- induced thrombocytopenia antibodies. Br J Haematol. 2017;179(5):811-819.
82. Platton S, Bartlett A, MacCallum P, et al. Evaluation of laboratory assays for anti- platelet factor 4 antibodies after ChAdOx1 nCOV-19 vaccination. J Thromb Haemost. 2021;19(8):2007-2013.
83. Cines DB, Bussel JB. SARS-CoV-2 Vaccine- induced immune thrombotic thrombocy- topenia. N Engl J Med. 2021;384(23):2254- 2256.
84. Sørvoll IH, Horvei KD, Ernstsen SL, et al. An observational study to identify the prevalence of thrombocytopenia and anti- PF4/polyanion antibodies in Norwegian health care workers after COVID-19 vacci- nation. J Thromb Haemost. 2021;19(7): 1813-1818.
85. Thiele T, Ulm L, Holtfreter S, et al. Frequency of positive anti-PF4/polyanion antibody tests after COVID-19 vaccination with ChAdOx1 nCoV-19 and BNT162b2. Blood. 2021;138(4):299-303.
86. Kowarz E, Krutzke L, Reis J, Bracharz S, Kochanek S, Marschalek R. Vaccine- induced Covid-19 spike open reading frame results in spike protein variant that may cause thromboembolic events in patients immunized with vector-based vac- cine. Research Square. 2021 May 26. [Epub ahead of print]
87. Lei Y, Zhang J, Schiavon CR, et al. SARS- CoV-2 spike protein impairs endothelial function via downregulation of ACE 2. Circ Res. 2021;128(9):1323-1326.
88. Chakraborty S, Gonzalez J, Edwards K. Proinflammatory IgG Fc structures in patients with severe COVID-19. Nat Immunol. 2021;22(1):67-73.
89. Douxfils J, Favresse J, Dogné JM. Hypotheses behind the very rare cases of thrombosis with thrombocytopenia syn- drome after SARS-CoV-2 vaccination. Thromb Res. 2021;203:163-171.
90. Shen S, Zhang J, Fang Y, et al. SARS-CoV-2 interacts with platelets and megakary- ocytes via ACE2-independent mechanism. J Hematol Oncol. 2021;29;14(1):72.
91. Millington-Burgess SL, Harper MT. A dou- ble-edged sword: antibody-mediated pro- coagulant platelets in COVID-19. Platelets. 2021; 32(5):579-581.
92. Choi PHI. Thrombotic thrombocytopenia after ChAdOx1 nCoV-19 vaccination. N Engl J Med. 2021;385(3):e11.
haematologica | 2021; 106(12)
3045